Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target

GeneDx Holdings Corp. (NASDAQ:WGS) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target

On March 12, 2026, Craig-Hallum reaffirmed its Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) and maintained a price target of $153 on the company’s stock following data presented at the ACMG Annual Meeting. The data indicated that the company’s whole exome and genome testing notably reduces healthcare resource utilization and total healthcare costs. Analysts believe these findings strengthen GeneDx Holdings Corp. (NASDAQ:WGS)’s capabilities in the commercial and Medicaid coverage expansion. The firm remains bullish despite the company’s shares witnessing a 9% decline on the same day, after its competitor Natera launched its Zenith genomics assay, which aims at offering improved detection of rare diseases.

Separately, on February 24, 2026, BTIG analyst Mark Massaro maintained the firm’s Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) but adjusted the price target from $200 to $170. The firm remains bullish following a strong Q4 beat and also expressed confidence in the company’s fundamentals and new opportunities.

Founded in 2000, GeneDx Holdings Corp. (NASDAQ:WGS) is a leader in rare disease genomics and exome/genome sequencing, with headquarters in Maryland.

While we acknowledge the risk and potential of WGS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WGS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.